FrancophonIA/ELRC3.0 huggingface dataset:
English: As dangerously low numbers of a certain type of white blood cell needed to fight infection in your blood has been seen very rarely with patients taking INVEGA, your doctor may check your white blood cell counts.
Croatian: Budući da je u bolesnika koji uzimaju INVEGU vrlo rijetko zabilježen opasno nizak broj određene vrste bijelih krvnih stanica koje su potrebne za borbu protv infekcije, liječnik vam može provjeriti broj bijelih krvnih stanica.
English: Switching to other antipsychotic medicinal products There are no systematically collected data to specifically address switching patients from INVEGA to other antipsychotic medicinal products.
Croatian: Ne postoje sustavno prikupljeni podaci koji se odnose specifično na bolesnike koji prelaze s lijeka INVEGA na druge antipsihotičke lijekove.
English: The trial was stopped early for efficacy reasons by showing a significantly longer time to relapse in patients treated with INVEGA compared to placebo (p=0.0053).
Croatian: Ispitivanje je zbog djelotvornosti prekinuto ranije pokazujući značajno dulje vrijeme do relapsa bolesti kod bolesnika koji su primali lijek INVEGA u usporedbi s placebom (p = 0,0053).
English: Conditions with decreased gastro-intestinal transit time Conditions leading to shorter gastrointestinal transit time, e.g., diseases associated with chronic severe diarrhoea, may result in a reduced absorption of paliperidone.
Croatian: Stanja s ubrzanim prolazom sadržaja kroz gastrointestinalni trakt Stanja koja vode do skraćenog prolaza kroz gastrointestinalni trakt, npr. bolesti vezane uz kronični proljev mogu uzrokovati smanjenu apsorpciju paliperidona.
English: Patients with a history of a clinically significant low white blood cell count (WBC) or a drug-induced leucopenia/neutropenia should be monitored during the first few months of therapy and discontinuation of INVEGA should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.
Croatian: Bolesnike s klinički značajnim sniženjem broja leukocita u povijesti bolesti ili leukopenijom/neutropenijom koja je izazvana lijekovima, treba pratiti tijekom prvih nekoliko mjeseci liječenja, a na prvi znak klinički značajnog pada leukocita, bez prisustva drugih uzročnih faktora, u obzir treba uzeti prestanak uzimanja INVEGE.
English: Medicinal products affecting gastrointestinal transit time may affect the absorption of paliperidone, e.g., metoclopramide.
Croatian: Lijekovi koji utječu na vrijeme prolaza sadržaja kroz gastrointestinalni trakt mogu utjecati na apsorpciju paliperidona, npr. metoklopramid.
English: • convulsion (fits), fainting, a restless urge to move parts of your body, dizziness upon standing, disturbance in attention, problems with speech, loss or abnormal sense of taste, reduced sensation of skin to pain and touch, a sensation of tingling, pricking, or numbness of skin
Croatian: • konvulzije (napadaji), kratkotrajna nesvjestica, nestrpljiva potreba za pokretanjem dijelova tijela, omaglica nakon ustajanja, poremećaj pažnje, problem s govorom, gubitak ili nenormalan osjet okusa, smanjen osjećaj kože na bol i dodir, osjećaj peckanja, bockanja ili obamrlosti kože
English: The use of oral risperidone together with this medicine is not recommended as the combination of the two medicines may lead to increased side effects.
Croatian: Uzimanje risperidona kroz usta zajedno s ovim lijekom se ne preporučuje jer kombinacija ova dva lijeka može dovesti do povećanja nuspojava.
English: Adverse reactions that may suggest increase in prolactin levels (e.g., amenorrhoea, galactorrhoea, menstrual disturbances, gynaecomastia) were reported overall in 9.3% of subjects.
Croatian: Nuspojave koje mogu ukazivati na povišene razine prolaktina (npr. amenoreja, galaktoreja, poremećaj menstruacije, ginekomastija) općenito su bile prijavljene u 9,3% ispitanika.
English: Events of leucopenia, neutropenia, and agranulocytosis have been reported with antipsychotic agents, including INVEGA.
Croatian: Leukopenija, neutropenija i agranulocitoza bile su prijavljene uz antipsihotike, uključujući i INVEGU.
English: • ear infection
Croatian: • infekcija uha
English: The efficacy of INVEGA in adolescent subjects with schizophrenia (INVEGA N = 149, placebo N = 51) was studied in a randomised, double-blind, placebo-controlled, 6-week study using a fixed-dose weight-based treatment group design over the dose range of 1.5 mg/day to 12 mg/day.
Croatian: Djelotvornost lijeka INVEGA u adolescenata sa shizofrenijom (INVEGA N = 149, placebo N = 51) bila je ispitana u randomiziranom, dvostruko slijepom, placebom kontroliranom ispitivanju u trajanju od 6 tjedana s dizajnom skupine koja je liječena fiksnom dozom temeljenoj na tjelesnoj težini u rasponu doza od 1,5 mg/dan do 12 mg/dan.
English: Other signs of parkinsonism include a slow shuffling walk, a tremor while at rest, increased saliva and/or drooling, and a loss of expression on the face.
Croatian: Ostali znakovi parkinsonizma uključuju spori hod uz vučenje nogu, tremor u mirovanju, pojačano lučenje sline i/ili slinjenje i gubitak izraza lica.
English: • decreased oxygen in parts of your body (because of decreased blood flow), flushing
Croatian: • smanjenje kisika u dijelovima tijela (zbog smanjenja protoka krvi), crvenilo uz osjećaj vrućine
English: The efficacy of INVEGA in the acute treatment of psychotic or manic symptoms of schizoaffective disorder was established in two placebo-controlled, 6-week trials in non-elderly adult subjects.
Croatian: Djelotvornost lijeka INVEGA u akutnom liječenju psihotičnih ili maničnih simptoma shizoafektivnog poremećaja utvrđena je u dva placebom kontrolirana ispitivanja u trajanju od 6 tjedana kod odraslih ispitanika koji nisu starije dobi.
English: • dystonia: This is a condition involving slow or sustained involuntary contraction of muscles.
Croatian: • distonija: Ovo stanje uključuje spore ili kontinuirane nevoljne mišićne kontrakcije.
English: Neonates exposed to antipsychotics (including paliperidone) during the third trimester of pregnancy are at risk of adverse reactions including extrapyramidal and/or withdrawal symptoms that may vary in severity and duration following delivery.
Croatian: U novorođenčadi koja su tijekom trećeg tromjesečja trudnoće izložena antipsihoticima (uključujući paliperidon), postoji rizik pojave nuspojava koje uključuju ekstrapiramidne simptome i/ili simptome ustezanja, koje mogu varirati u težini i trajanju nakon rođenja.
English: Repeat-dose toxicity studies of paliperidone in rat and dog showed mainly pharmacological effects, such as sedation and prolactin-mediated effects on mammary glands and genitals.
Croatian: Ispitivanja toksičnosti ponovljenih doza paliperidona na štakorima i psima pokazala su pretežno farmakološke učinke, poput sedacije i promjena na mliječnim žlijezdama i genitalijama izazvane prolaktinom.
English: Conversely, on discontinuation of carbamazepine, the dose of INVEGA should be re-evaluated and decreased if necessary.
Croatian: Obrnuto, kad se karbamazepin ukida, dozu lijeka INVEGA trebalo bi ponovno procijeniti te ako je potrebno smanjiti.
English: Concomitant use of INVEGA with psychostimulants The combined use of psychostimulants (e.g., methylphenidate) with paliperidone can lead to extrapyramidal symptoms upon change of either or both treatments (see section 4.4).
Croatian: Istodobna primjena lijeka INVEGA sa psihostimulansima Istodobna primjena psihostimulansa (npr. metilfenidata) i paliperidona može dovesti do ekstrapiramidnih simptoma prilikom promjene u terapiji jednim ili drugim lijekom (vidjeti dio 4.4).
English: How and when to take INVEGA
Croatian: Kako i kada uzeti lijek INVEGA
English: Population pharmacokinetics analysis revealed no evidence of race-related differences in the pharmacokinetics of paliperidone following INVEGA administration.
Croatian: Analiza populacijske farmakokinetike nije ukazala na s rasom povezane razlike u farmakokinetici paliperidona nakon primjene lijeka INVEGA
English: With once-daily dosing of INVEGA, steady-state concentrations of paliperidone are attained within 4-5 days of dosing in most subjects.
Croatian: Uz jednu dozu lijeka INVEGA dnevno, stanje dinamičke ravnoteže koncentracija paliperidona kod većine ispitanika se doseže unutar 4 do 5 dana uzimanja lijeka.
English: In a study conducted in elderly subjects with schizophrenia, the safety profile was similar to that seen in non-elderly subjects.
Croatian: U ispitivanju provedenom u starijih shizofrenih ispitanika, sigurnosni profil je bio sličan zapaženom i kod mlađih ispitanika.
English: Since patients treated with antipsychotics often present with acquired risk factors for VTE, all possible risk factors for VTE should be identified before and during treatment with INVEGA and preventive measures undertaken.
Croatian: Budući da bolesnici koji se liječe antipsihoticima često imaju stečene faktore rizika za razvoj venske tromboembolije, prije i tijekom liječenja lijekom INVEGA potrebno je utvrditi sve moguće faktore rizika za vensku tromboemboliju i poduzeti preventivne mjere.
English: INVEGA Medium Dose 3 or 6 mg* N=48
Croatian: Srednja doza 3 ili 6 mg* N=48
English: The active ingredient, paliperidone, dissolves once swallowed and the tablet shell is passed out of the body as waste.
Croatian: Djelatna tvar, paliperidon, se otapa nakon gutanja, a ovojnica tablete prolazi kroz tijelo te se izbacuje kao tjelesni otpad.
English: Pack sizes of 30 and 350 prolonged-release tablets.
Croatian: Veličine pakiranja su od 30 i 350 tableta s produljenim oslobađanjem.
English: • blood clots in the veins especially in the legs (symptoms include swelling, pain and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing.
Croatian: • se pojave krvni ugrušci u venama, naročito u nogama (simptomi uključuju oticanje, bol i crvenilo noge), koji se mogu kretati kroz krvne žile prema plućima i uzrokovati bol u prsima i teškoće s disanjem.
English: Based on pooled data from the three, placebo-controlled, 6-week, fixed-dose trials with INVEGA (3, 6, 9, and 12 mg), orthostatic hypotension was reported by 2.5% of subjects treated with INVEGA compared with 0.8% of subjects treated with placebo.
Croatian: Na temelju skupnih podataka iz tri placebom kontrolirana ispitivanja s fiksnom dozom lijeka INVEGA (3, 6, 9 i 12 mg), u trajanju od 6 tjedana, ortostatska hipotenzija zabilježena je u 2,5% bolesnika liječenih peroralnim paliperidonom, u usporedbi s 0,8% ispitanika koji su primali placebo.
English: Population pharmacokinetics analyses indicated no discernible difference on the apparent clearance of paliperidone after administration of INVEGA between extensive metabolisers and poor metabolisers of CYP2D6 substrates.
Croatian: Analiza populacijske farmakokinetike nije pokazala zamjetnu razliku u prividnom klirensu paliperidona nakon primjene lijeka INVEGA između brzih i sporih metabolizatora supstrata CYP2D6.
English: For patients with moderate to severe renal impairment (creatinine clearance  10 to < 50 mL/min), the recommended initial dose of INVEGA is 3 mg every other day, which may be increased to 3 mg once daily after clinical reassessment.
Croatian: Kod bolesnika s umjerenim do teškim oštećenjem bubrega (klirens kreatinina  10 do < 50 ml/min) preporučuje se inicijalna doza lijeka INVEGA od 3 mg svaki drugi dan, koja se može povećati na 3 mg jednom dnevno nakon ponovne kliničke procjene.
English: An approximately 3-fold increased risk of cerebrovascular adverse reactions have been seen in randomised placebo-controlled clinical trials in the dementia population with some atypical antipsychotics, including risperidone, aripiprazole, and olanzapine.
Croatian: U randomiziranim, placebo-kontroliranim kliničkim ispitivanjima u populaciji s demencijom, zabilježen je oko 3 puta veći rizik za cerebrovaskularne nuspojave uz primjenu atipičnih antipsihotika, uključujući risperidon, aripiprazol i olanzapin.
English: In rat reproduction studies using risperidone, which is extensively converted to paliperidone in rats and humans, a reduction was observed in the birth weight and survival of the offspring.
Croatian: U ispitivanjima reprodukcije na štakorima s peroralno primijenjenim risperidonom koji se u velikoj mjeri pretvara u paliperidon i u štakora i u ljudi, uočeni su negativni učinci na porođajnu težinu i preživljavanje potomaka.
English: INVEGA should be used with caution in elderly patients with dementia who have risk factors for stroke.
Croatian: INVEGA se treba primjenjivati uz oprez u starijih bolesnika s demencijom koji imaju faktore rizika za moždani udar.
English: • an increase of CPK (creatine phosphokinase) in your blood, an enzyme which is sometimes released with muscle breakdown, muscle spasms, joint stiffness, joint swelling, muscle weakness, neck pain
Croatian: • povišenje CPK (keratin fosfokinaza) u krvi, enzim koji se ponekad oslobađa pri pucanju mišića, mišićni grčevi, ukočenost zglobova, oticanje zglobova, mišićna slabost, bol u vratu
English: If a patient develops signs or symptoms indicative of NMS, all antipsychotics, including INVEGA, should be discontinued.
Croatian: Ukoliko se kod bolesnika pojave znakovi ili simptomi koji upućuju na MNS, potrebno je prekinuti uzimanje svih antipsihotika, uključujući i INVEGU.
English: Dizziness and vision problems may occur during treatment with this medicine (see section 4, possible side effects).
Croatian: Tijekom liječenja ovim lijekom mogu se javiti omaglica i problemi s vidom (vidjeti dio 4, moguće nuspojave).
English: Administration of paliperidone prolonged-release tablets with a standard high-fat/high-caloric meal increases Cmax and AUC of paliperidone by up to 50-60% compared with administration in the fasting state.
Croatian: Uzimanje tableta s produljenim otpuštanjem paliperidona uz standardni visokokalorični obrok s velikim udjelom masnoća, povećava Cmax i AUC paliperidona za do 50-60% u usporedbi s uzimanjem lijeka natašte.
English: • sensation of spinning (vertigo).
Croatian: • osjećaj vrćenja (vrtoglavica).
English: Caution is advised when prescribing INVEGA with medicines known to prolong the QT interval, e.g., class IA antiarrhythmics (e.g., quinidine, disopyramide) and class III antiarrhythmics (e.g., amiodarone, sotalol), some antihistaminics, some other antipsychotics and some antimalarials (e.g., mefloquine).
Croatian: Preporučuje se oprez kad se INVEGA propisuje zajedno s lijekovima za koje je poznato da produljuju QT interval, npr. antiaritmicima skupine IA (npr. kinidin, dizopiramid) i antiaritmicima skupine III (npr. amiodaron, sotalol), nekim antihistaminicima, nekim drugim antipsihoticima i nekim antimalaricima (npr. meflokin).
English: • feeling sleepy or less alert
Croatian: • osjećaj pospanosti ili smanjene pozornosti
English: Adverse reactions that may suggest increase in prolactin levels (e.g., amenorrhoea, galactorrhoea, menstrual disturbances, gynaecomastia) were reported overall in 2% of subjects.
Croatian: Nuspojave koje mogu ukazivati na povećane razine prolaktina (npr. amenoreja, galaktoreja, poremećaj menstruacije, ginekomastija) bile su zabilježene u ukupno 2% ispitanika.
English: INVEGA contains the active substance paliperidone which belongs to the class of antipsychotic medicines.
Croatian: INVEGA sadrži djelatnu tvar paliperidon, pripada skupini lijekova koji se zovu antipsihotici.
English: In schizophrenia clinical trials, the proportions of subjects meeting a weight gain criterion of ≥ 7% of body weight were compared, revealing a similar incidence of weight gain for INVEGA 3 mg and 6 mg compared with placebo, and a higher incidence of weight gain for INVEGA 9 mg and 12 mg compared with placebo.
Croatian: U kliničkim ispitivanjima kod shizofrenih bolesnika uspoređivani su udjeli ispitanika koji su ispunjavali kriterij povećanja težine za ≥ 7%, pri čemu je otkrivena slična incidencija povećanja težine uz lijek INVEGA u dozama 3 mg i 6 mg u usporedbi s placebom, te veća incidencija povećanja težine uz lijek INVEGA od 9 mg i 12 mg u usporedbi s placebom.
English: As INVEGA has not been studied in patients with creatinine clearance below 10 mL/min, use is not recommended in such patients.
Croatian: Budući da INVEGA nije ispitana u bolesnika s klirensom kreatinina ispod 10 ml/min, takvim se bolesnicima ne preporučuje uzimanje ovog lijeka.
English: In the short-term, placebo-controlled, fixed-dose adolescent study, the incidence of EPS was higher than placebo for all doses of INVEGA with an increased frequency of EPS at higher doses.
Croatian: U kratkotrajnom, placebom-kontroliranom ispitivanju fiksne doze u adolescenata, incidencija EPS-a bila je viša nego za placebo za sve doze lijeka INVEGA s povećanom učestalošću EPS-a pri višim dozama.
English: Hyperglycaemia, diabetes mellitus, and exacerbation of pre-existing diabetes have been reported during treatment with paliperidone.
Croatian: Hiperglikemija, dijabetes melitus i egzacerbacija već postojećeg dijabetesa prijavljeni su tijekom liječenja paliperidonom.
English: • severe allergic reaction characterised by fever, swollen mouth, face, lip or tongue, shortness of breath, itching, skin rash and sometimes drop in blood pressure, allergic reaction
Croatian: • teška alergijska reakcija koju karakterizira vrućica, otečena usta, lice, usne ili jezik, nedostatak zraka, svrbež, kožni osip i ponekad pad krvnog tlaka, alergijska reakcija
English: Metabolism and nutrition disorders weight increased, increased appetite, weight decreased, decreased appetite diabetes mellitus d,
Croatian: Poremećaji metabolizma i prehrane povećana težina, pojačan apetit, smanjena tjelesna težina, smanjen apetit dijabetes melitus d,
English: Excipient with known effect Each 3 mg tablet contains 13.2 mg lactose.
Croatian: Pomoćna tvar s poznatim učinkom Jedna tableta od 3 mg sadrži 13,2 mg laktoze.
English: Because the INVEGA tablet is non-deformable and does not appreciably change shape in the gastrointestinal tract, INVEGA should not ordinarily be administered to patients with preexisting severe gastrointestinal narrowing (pathologic or iatrogenic) or in patients with dysphagia or significant difficulty in swallowing tablets.
Croatian: Tableta INVEGA je nepromjenjiva oblika te joj se oblik ne mijenja znatno u gastrointestinalnom traktu, stoga se ne preporučuje davati bolesnicima s poznatim izrazitim suženjem (patološko ili jatrogeno) gastrointestinalnog trakta, kao ni bolesnicima s disfagijom, ili onima sa znatnim poteškoćama pri gutanju tableta.
English: Concomitant use of INVEGA with oral risperidone is not recommended as paliperidone is the active metabolite of risperidone and the combination of the two may lead to additive paliperidone exposure.
Croatian: Ne preporučuje se istodobna primjena lijeka INVEGA s peroralnim risperidonom budući je paliperidon aktivni metabolit risperidona i kombinacija ta dva lijeka može dovesti do dodatne izloženosti paliperidonu.
English: In schizophrenia clinical trials, there was no difference observed between placebo and the 3 and 6 mg doses of INVEGA.
Croatian: U kliničkim ispitivanjima kod shizofrenih bolesnika nije utvrđena razlika između placeba i doza od 3 mg i 6 mg lijeka INVEGA.
English: • low blood pressure upon standing (consequently, some people taking INVEGA may feel faint,
Croatian: • nizak krvni tlak nakon ustajanja (kao posljedica toga, neki ljudi koji uzimaju INVEGU mogu osjećati nesvjesticu, omaglicu ili se mogu onesvjestiti nakon što iznenada ustanu ili sjednu),
English: Co-administration of INVEGA 12 mg once daily with divalproex sodium prolonged-release tablets (500 mg to 2,000 mg once daily) did not affect the steady-state pharmacokinetics of valproate.
Croatian: Istovremena primjena INVEGE od 12 mg jednom dnevno i tableta divalproeksnatrija s produljenim oslobađanjem (500 mg do 2000 mg jednom dnevno) nije utjecala na farmakokinetiku valproata u stanju dinamičke ravnoteže.
English: - if you have ever been diagnosed with a condition whose symptoms include high temperature and muscle stiffness (also known as Neuroleptic Malignant Syndrome).
Croatian: - ako bolujete od Parkinsonove bolesti ili demencije. - ako Vam je ikad prije bilo dijagnosticirano stanje koje uključuje i slijedeće simptome: visoku temperaturu i ukočenost mišića (također poznato kao maligni neuroleptički sindrom).
English: Safety and efficacy of INVEGA in patients > 65 years of age with schizoaffective disorder have not been studied.
Croatian: Nije istražena sigurnost i djelotvornost lijeka INVEGA kod bolesnika > 65 godina koji boluju od shizoafektivnog poremećaja.
English: • experience a severe allergic reaction characterised by fever, swollen mouth, face, lip or tongue, shortness of breath, itching, skin rash and sometimes drop in blood pressure (amounting to an ‘anaphylactic reaction').
Croatian: • doživite tešku alergijsku reakciju koja se očituje vrućicom, naticanjem usta, lica, usana ili jezika, nedostatkom zraka, svrbežom, kožnim osipom i ponekad padom krvnog tlaka (što vodi do „anafilaktičke reakcije”).
English: There have been rare reports of obstructive symptoms in patients with known strictures in association with the ingestion of medicines in non-deformable controlled-release formulations.
Croatian: Rijetko su kod bolesnika s poznatim strikturama, zabilježeni opstruktivni simptomi povezani s ingestijom lijekova s produljenim otpuštanjem u obliku koji se ne mijenja.
English: In the lower dose group of the 2 dose-level study (6 mg/day with option to reduce to 3 mg/day), INVEGA was not significantly different from placebo as measured by the PANSS.
Croatian: U skupini koja je liječena nižom dozom u ispitivanju 2 doze (6 mg/dan s mogućnošću smanjenja na 3 mg/dan), INVEGA se nije statistički razlikovala od placeba mjereno PANSS.
English: In the schizoaffective disorder studies, the incidence of EPS was observed at a higher rate than placebo in all dose groups without a clear relationship to dose.
Croatian: U ispitivanjima kod bolesnika s shizoafektivnim poremećajem zapažena je incidencija EPS koja je bila viša u odnosu na placebo u svim doznim skupinama bez jasne povezanosti s dozom.
English: However, elderly patients with dementia, who are treated with other similar types of medicine, may have an increased risk of stroke or death.
Croatian: Međutim, stariji bolesnici s demencijom koji se liječe drugim sličnim lijekovima mogu imati povećan rizik od moždanog udara ili smrti. (vidjeti dio 4, Moguće nuspojave).
English: Responder, n (%) Non-responder, n (%) P value (vs Placebo)
Croatian: Odgovor na liječenje, n (%) Bez odgovora, n (%) P vrijednost (vs Placebo)
English: Paliperidone was not genotoxic in a battery of tests.
Croatian: Paliperidon nije bio genotoksičan u nizu ispitivanja.
English: The active substance is paliperidone
Croatian: Djelatna tvar je paliperidon
English: INVEGA is indicated for the treatment of schizoaffective disorder in adults.
Croatian: INVEGA je indicirana za liječenje shizoafektivnog poremećaja u odraslih.
English: Janssen-Cilag SpA Via C. Janssen IT-04100 Borgo San Michele Latina
Croatian: Janssen IT-04100 Borgo San Michele Latina
English: INVEGA should be used cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold.
Croatian: Lijek INVEGA potrebno je koristiti s oprezom kod bolesnika s epilepsijom ili kod drugih stanja koja bi potencijalno mogla sniziti konvulzivni prag.
English: However, there was no discernable effect of age in the population pharmacokinetic analysis involving schizophrenia subjects after correction of age-related decreases in CrCl.
Croatian: Međutim, značajan utjecaj dobi u analizi populacijske farmakokinetike koja je uključivala shizofrene bolesnike nije uočen nakon korekcije smanjivanja CrCl-a prema dobi.
English: INVEGA has not been studied in elderly patients with dementia.
Croatian: INVEGA nije ispitana kod starijih bolesnika s demencijom.
English: Hyperglycemia and diabetes mellitus
Croatian: Hiperglikemija i dijabetes melitus
English: The apparent volume of distribution is 487 L. The plasma protein binding of paliperidone is 74%.
Croatian: Vezanje paliperidona na proteine plazme iznosi 74%.